Jason Lettmann is the CEO of ALX Oncology Holdings Inc., a biotech company focused on developing cancer treatments. He has a solid educational background with a B.A. in Psychology from the University of Iowa and an M.B.A. from the University...
Jason Lettmann is the CEO of ALX Oncology Holdings Inc., a biotech company focused on developing cancer treatments. He has a solid educational background with a B.A. in Psychology from the University of Iowa and an M.B.A. from the University of Michigan. This combination of skills helps him manage the company effectively in a challenging industry. Lettmann was appointed CEO on September 6, 2023, after serving on the company's board since 2020. Before this role, he held key positions at several other firms, including being CEO of Promedior and a partner at Morgenthaler Ventures. His experience includes significant roles in venture capital and biotechnology, which gives him a well-rounded view of the business. In 2023, he received a total compensation of $487,183, which included a salary of $217,330 and a bonus. Lettmann has a strong business mindset, aiming to align the goals of executives with those of stockholders. Also notable is his recent insider trading activity, where he reported values in holdings reaching up to $9.81 million back in August 2020, reflecting his strong commitment to the company he leads. Lettmann continues to drive the company forward, leveraging his expertise and experience in the biotech space.